Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie, Linong Ji. J Am Heart Assoc 2020
Times Cited: 2
Times Cited: 2
Times Cited
Times Co-cited
Similarity
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
100
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
100
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
100
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
100
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
100
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
100
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
100
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
J Liutkus, J Rosas Guzman, P Norwood, L Pop, J Northrup, D Cao, M Trautmann. Diabetes Obes Metab 2010
J Liutkus, J Rosas Guzman, P Norwood, L Pop, J Northrup, D Cao, M Trautmann. Diabetes Obes Metab 2010
50
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
Peter N Weissman, Molly C Carr, June Ye, Deborah T Cirkel, Murray Stewart, Caroline Perry, Richard Pratley. Diabetologia 2014
Peter N Weissman, Molly C Carr, June Ye, Deborah T Cirkel, Murray Stewart, Caroline Perry, Richard Pratley. Diabetologia 2014
50
Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
R E Pratley, D Urosevic, M Boldrin, R Balena. Diabetes Obes Metab 2013
R E Pratley, D Urosevic, M Boldrin, R Balena. Diabetes Obes Metab 2013
50
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Christopher Lee, Jisoo Lee, Jyothis George. Diabetes Obes Metab 2018
Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Christopher Lee, Jisoo Lee, Jyothis George. Diabetes Obes Metab 2018
50
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
50
Diabetes and Hypertension: A Position Statement by the American Diabetes Association.
Ian H de Boer, Sripal Bangalore, Athanase Benetos, Andrew M Davis, Erin D Michos, Paul Muntner, Peter Rossing, Sophia Zoungas, George Bakris. Diabetes Care 2017
Ian H de Boer, Sripal Bangalore, Athanase Benetos, Andrew M Davis, Erin D Michos, Paul Muntner, Peter Rossing, Sophia Zoungas, George Bakris. Diabetes Care 2017
50
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
50
GLP-1 Is a Coronary Artery Vasodilator in Humans.
Sophie J Clarke, Joel P Giblett, Lucy L Yang, Annette Hubsch, Tian Zhao, Muhammad Aetesam-Ur-Rahman, Nick E J West, Michael O'Sullivan, Nichola Figg, Martin Bennett,[...]. J Am Heart Assoc 2018
Sophie J Clarke, Joel P Giblett, Lucy L Yang, Annette Hubsch, Tian Zhao, Muhammad Aetesam-Ur-Rahman, Nick E J West, Michael O'Sullivan, Nichola Figg, Martin Bennett,[...]. J Am Heart Assoc 2018
50
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
50
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
50
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
50
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
50
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
50
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
Vivian A Fonseca, J Hans Devries, Robert R Henry, Morten Donsmark, Henrik F Thomsen, Jorge Plutzky. J Diabetes Complications 2014
Vivian A Fonseca, J Hans Devries, Robert R Henry, Morten Donsmark, Henrik F Thomsen, Jorge Plutzky. J Diabetes Complications 2014
50
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Julie A Lovshin, Annette Barnie, Ariana DeAlmeida, Alexander Logan, Bernard Zinman, Daniel J Drucker. Diabetes Care 2015
Julie A Lovshin, Annette Barnie, Ariana DeAlmeida, Alexander Logan, Bernard Zinman, Daniel J Drucker. Diabetes Care 2015
50
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
50
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
E Araki, N Inagaki, Y Tanizawa, T Oura, M Takeuchi, T Imaoka. Diabetes Obes Metab 2015
E Araki, N Inagaki, Y Tanizawa, T Oura, M Takeuchi, T Imaoka. Diabetes Obes Metab 2015
50
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
Melanie J Davies, Stephen C Bain, Stephen L Atkin, Peter Rossing, David Scott, Minara S Shamkhalova, Heidrun Bosch-Traberg, Annika Syrén, Guillermo E Umpierrez. Diabetes Care 2016
Melanie J Davies, Stephen C Bain, Stephen L Atkin, Peter Rossing, David Scott, Minara S Shamkhalova, Heidrun Bosch-Traberg, Annika Syrén, Guillermo E Umpierrez. Diabetes Care 2016
50
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Keith C Ferdinand, William B White, David A Calhoun, Eva M Lonn, Philip T Sager, Rocco Brunelle, Honghua H Jiang, Rebecca J Threlkeld, Kenneth E Robertson, Mary Jane Geiger. Hypertension 2014
Keith C Ferdinand, William B White, David A Calhoun, Eva M Lonn, Philip T Sager, Rocco Brunelle, Honghua H Jiang, Rebecca J Threlkeld, Kenneth E Robertson, Mary Jane Geiger. Hypertension 2014
50
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.
Linong Ji, Yukiko Onishi, Chul Woo Ahn, Pankaj Agarwal, Chien-Wen Chou, Harry Haber, Kelly Guerrettaz, Marilyn K Boardman. J Diabetes Investig 2013
Linong Ji, Yukiko Onishi, Chul Woo Ahn, Pankaj Agarwal, Chien-Wen Chou, Harry Haber, Kelly Guerrettaz, Marilyn K Boardman. J Diabetes Investig 2013
50
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
J Rosenstock, L J Seman, A Jelaska, S Hantel, S Pinnetti, T Hach, H J Woerle. Diabetes Obes Metab 2013
J Rosenstock, L J Seman, A Jelaska, S Hantel, S Pinnetti, T Hach, H J Woerle. Diabetes Obes Metab 2013
50
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Ted Okerson, Ping Yan, Anthony Stonehouse, Robert Brodows. Am J Hypertens 2010
Ted Okerson, Ping Yan, Anthony Stonehouse, Robert Brodows. Am J Hypertens 2010
50
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,[...]. Expert Opin Pharmacother 2014
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,[...]. Expert Opin Pharmacother 2014
50
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Volker Vallon. Annu Rev Med 2015
Volker Vallon. Annu Rev Med 2015
50
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Edward S Horton, Cheryl Silberman, Keith L Davis, Rachele Berria. Diabetes Care 2010
Edward S Horton, Cheryl Silberman, Keith L Davis, Rachele Berria. Diabetes Care 2010
50
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Thomas J Moretto, Denái R Milton, Terry D Ridge, Leigh A Macconell, Ted Okerson, Anne M Wolka, Robert G Brodows. Clin Ther 2008
Thomas J Moretto, Denái R Milton, Terry D Ridge, Leigh A Macconell, Ted Okerson, Anne M Wolka, Robert G Brodows. Clin Ther 2008
50
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
50
Serum sodium concentration and risk of stroke in middle-aged males.
G Wannamethee, P H Whincup, A G Shaper, A F Lever. J Hypertens 1994
G Wannamethee, P H Whincup, A G Shaper, A F Lever. J Hypertens 1994
50
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
50
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G Zimmermann, Valeria Pechtner. Diabetes Care 2015
Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G Zimmermann, Valeria Pechtner. Diabetes Care 2015
50
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
50
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
50
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
50
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Matthew R Weir, Andrzej Januszewicz, Richard E Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger. J Clin Hypertens (Greenwich) 2014
Matthew R Weir, Andrzej Januszewicz, Richard E Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger. J Clin Hypertens (Greenwich) 2014
50
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
50
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
K Kaku, A Kiyosue, S Inoue, N Ueda, T Tokudome, J Yang, A M Langkilde. Diabetes Obes Metab 2014
K Kaku, A Kiyosue, S Inoue, N Ueda, T Tokudome, J Yang, A M Langkilde. Diabetes Obes Metab 2014
50
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Juan P Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Fang Dong, Peter Öhman, Serge A Jabbour. Lancet Diabetes Endocrinol 2016
Juan P Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Fang Dong, Peter Öhman, Serge A Jabbour. Lancet Diabetes Endocrinol 2016
50
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
50
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Chieh-Hsiang Lu, Kyung Wan Min, Lee-Ming Chuang, Satoshi Kokubo, Satoshi Yoshida, Bong-Soo Cha. J Diabetes Investig 2016
Chieh-Hsiang Lu, Kyung Wan Min, Lee-Ming Chuang, Satoshi Kokubo, Satoshi Yoshida, Bong-Soo Cha. J Diabetes Investig 2016
50
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
A Ahmann, H W Rodbard, J Rosenstock, J T Lahtela, L de Loredo, K Tornøe, A Boopalan, M A Nauck. Diabetes Obes Metab 2015
A Ahmann, H W Rodbard, J Rosenstock, J T Lahtela, L de Loredo, K Tornøe, A Boopalan, M A Nauck. Diabetes Obes Metab 2015
50
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.